Alpha Teknova has launched the next set of reagents in the company’s proprietary product line, AAV-Tek Solutions. Available for purchase starting today is a version of Teknova’s AAV-Tek AEX Buffer Screening Kit for the AAV8 serotype, along with a suite of reagents to support the entire gene therapy workflow.
“After we introduced our first proprietary gene therapy product a few months ago – the AAV-Tek AEX Buffer Screening Kit for AAV2 – customers encouraged us to create additional solutions to better support AAV gene therapy developers,” said Stephen Gunstream, Teknova’s President and CEO.
“In a few short months, our talented team has delivered the AEX Buffer Screening Kit for AAV8, specifically designed to help gene therapy developers save months in process development time. We’re also making available more than 20 additional reagents we’ve identified as key solutions to support the entire gene therapy workflow.”
The AAV-Tek AEX Buffer Screening Kit was created to help streamline the identification of the ideal buffer formulation for use during AAV downstream processing, specifically during the anion exchange (AEX) purification step. Developed by Teknova’s Research and Development team, the kit addresses critical pain points in the workflow by providing a selection of serotype-specific equilibration and elution buffers to optimise the separation of empty and full capsids during polishing.
We’re also making available more than 20 additional reagents we’ve identified as key solutions to support the entire gene therapy workflow
- Stephen Gunstream, Teknova’s President and CEO
Teknova conducted a robust design of experiments across multiple AAV serotypes by monitoring four different critical quality attributes (infectivity, recovery, purity, and peak separation), to identify the optimal number of buffers for use across a variety of upstream workflows, transgenes, and downstream purification platforms.
Teknova is also introducing a suite of 24 high-quality, off-the-shelf reagents as part of the company’s AAV-Tek Solutions product line, including cell lysis solutions, filtration wash buffers, and capture chromatography reagents.
Designed to address end-to-end upstream and downstream bioprocessing needs, this array of new solutions – including the AAV-Tek AEX Buffer Screening Kit – positions Teknova as a single-source partner for gene therapy developers to help them streamline and scale their end-to-end biomanufacturing process development and enter the clinic faster.
Along with the kit for AAV2 launched previously, the AAV-Tek AEX Buffer Screening Kit for AAV8 is available today for purchase via phone, email, or online, and is priced at $1,000. Teknova is continuing to work on additional serotypes – AAV6, AAV9, and AAV5 – for release later this year.